Compare BridgeBio Pharma Inc (BBIO) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Palo Alto Networks Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Palo Alto Networks Inc trades at $383.98 (market cap $313.81B). The key difference: Palo Alto Networks Inc is far larger — about 18.9× BridgeBio Pharma Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | PANW | |
|---|---|---|
Market Cap | $16.61B | $313.81B |
Sector | Health | Technology |
52-Week High | $90.17 | $385.04 |
52-Week Low | $47.29 | $141.67 |
Enterprise Value | $18.16B | $312.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Palo Alto Networks (PANW) trades at $363.86, up 1.22% today, near its pivot point of $365. The stock shows strong bullish momentum with consistent earnings beats and robust revenue growth, reaching $9.22 billion in fiscal 2025. Technical indicators signal bullish trends, while high valuation ratios like a P/E of 316.4 reflect market optimism. Recent news highlights AI-driven cybersecurity demand and record stock performance following industry events.
Outlook remains positive due to AI security tailwinds and earnings strength, but risks include premium valuation, integration costs from acquisitions, and regulatory scrutiny in China. Analyst consensus is strongly bullish with a $344.94 price target, though current price exceeds this, suggesting cautious optimism for growth-driven upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
